140 related articles for article (PubMed ID: 1726104)
1. Deoxyguanosine enhances the cytotoxicity of the topoisomerase I inhibitor camptothecin by reducing the repair of double-strand breaks induced in replicating DNA.
Squires S; Ryan AJ; Strutt HL; Smith PJ; Johnson RT
J Cell Sci; 1991 Dec; 100 ( Pt 4)():883-93. PubMed ID: 1726104
[TBL] [Abstract][Full Text] [Related]
2. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells.
Ryan AJ; Squires S; Strutt HL; Evans A; Johnson RT
Carcinogenesis; 1994 May; 15(5):823-8. PubMed ID: 8200082
[TBL] [Abstract][Full Text] [Related]
3. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
Znojek P; Willmore E; Curtin NJ
Br J Cancer; 2014 Sep; 111(7):1319-26. PubMed ID: 25003660
[TBL] [Abstract][Full Text] [Related]
4. DNA repair, cell cycle progression and cell death following camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Skierski J; Szumiel I
Cell Biochem Funct; 1998 Dec; 16(4):239-52. PubMed ID: 9857486
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA.
Squires S; Ryan AJ; Strutt HL; Johnson RT
Cancer Res; 1993 May; 53(9):2012-9. PubMed ID: 7683249
[TBL] [Abstract][Full Text] [Related]
6. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
7. Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxia-telangiectasia cells.
Johnson RT; Gotoh E; Mullinger AM; Ryan AJ; Shiloh Y; Ziv Y; Squires S
Biochem Biophys Res Commun; 1999 Aug; 261(2):317-25. PubMed ID: 10425184
[TBL] [Abstract][Full Text] [Related]
8. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
9. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells.
Jones CB; Clements MK; Redkar A; Daoud SS
Int J Oncol; 2000 Nov; 17(5):1043-51. PubMed ID: 11029511
[TBL] [Abstract][Full Text] [Related]
10. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells.
Yoshida A; Ueda T; Wano Y; Nakamura T
Jpn J Cancer Res; 1993 May; 84(5):566-73. PubMed ID: 8391526
[TBL] [Abstract][Full Text] [Related]
11. DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions.
Cristini A; Park JH; Capranico G; Legube G; Favre G; Sordet O
Nucleic Acids Res; 2016 Feb; 44(3):1161-78. PubMed ID: 26578593
[TBL] [Abstract][Full Text] [Related]
12. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
Wu J; Yin MB; Hapke G; Tóth K; Rustum YM
Mol Pharmacol; 2002 Apr; 61(4):742-8. PubMed ID: 11901212
[TBL] [Abstract][Full Text] [Related]
13. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.
O'Connor PM; Nieves-Neira W; Kerrigan D; Bertrand R; Goldman J; Kohn KW; Pommier Y
Cancer Commun; 1991 Aug; 3(8):233-40. PubMed ID: 1653585
[TBL] [Abstract][Full Text] [Related]
14. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
[TBL] [Abstract][Full Text] [Related]
15. The distinctive cellular responses to DNA strand breaks caused by a DNA topoisomerase I poison in conjunction with DNA replication and RNA transcription.
Sakasai R; Iwabuchi K
Genes Genet Syst; 2016; 90(4):187-94. PubMed ID: 26616758
[TBL] [Abstract][Full Text] [Related]
16. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
17. DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells.
Daza P; Torreblanca J; García-Herdugo G; Moreno FJ
Cell Biol Int; 2002; 26(8):707-13. PubMed ID: 12175674
[TBL] [Abstract][Full Text] [Related]
18. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
19. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
20. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Lei L; Xie X; He L; Chen K; Lv Z; Zhou B; Li Y; Hu W; Zhou Z
Invest New Drugs; 2021 Apr; 39(2):362-376. PubMed ID: 32981006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
